We observed a significant elevation of CXCL14 expression in tumour cells following TFRC knockdown, a result that aligns with the increased expression observed after anlotinib administration (p‐value < 0.05, Figures S9A–C and S10A). Here, CXCL14 is linked to neoplasm.